AVITA Medical Inc
ASX: AVH
Recell-driven growth narrows losses, with new launches and hospital expansion positioning for cash-flow improvement.
(Source: TradingView) 3-Month Performance Profile of AVH on a DTF compared to S&P/ASX 200 (XJO).
Avita Medical delivered a solid Q2 FY25 with revenue rising 24.6% YoY to $28.7 million, supported by deeper penetration of existing accounts, onboardin
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
